Servier is an international pharmaceutical company that was founded in 1883. It has been providing innovative, reliable products to patients for over 130 years. Besides being a global pharmaceutical company, it is also a very successful company in the cancer treatment market. In 2014, Servier generated 7.9 billion euros in revenues with 10,000 employees worldwide. One of the ways that Servier has been successful is through its research and development team. In 2015, Servier's research and development team met a milestone in cancer treatment when they helped develop a new cancer treatment which significantly improved the survival rates of patients with advanced head and neck cancer. The new drug called R-CHOP is a combination of two chemotherapy drugs that is designed to reduce mortality in patients with advanced head and neck cancer. With these new findings, Servier has generated a lot of interest from patients with this type of cancer and generated a market growth in the head and neck cancer market for which it can take advantage of with its products. In addition to its research and development team, Servier's leadership team is also responsible for growth in the company. This leadership team has helped to generate a lot of success by focusing on innovation and bringing out new products that are going to help the company grow globally. Servier offers a variety of products that can help people with many different types of health issues that arise from various diseases or conditions, such as cancer, diabetes, and cardiovascular disease. It also offers treatments such as stem cell therapy, orthopedic implants, and dental implants. Consumers should buy Servier because they offer innovative pharmaceutical products that can help with many different health problems and offer expert care for patients around the world through their research and development initiatives and their leadership team which helps to bring success for the company and its investors.